PRECIGEN, INC. GERMANTOWN, Md., May 28, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia.
- Pieter Rottiers, PhD, Chief Executive Officer of ActoBio Therapeutics, a wholly-owned subsidiary of Intrexon and innovative clinical-stage biotechnology company developing a new class of microbe-based therapeutic agents, will be giving a company presentation on Monday June 3rd from 2:15-2:30 pm ET.
- Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present in the session "It Starts with One Health: A Guide to Translational Science from Research to Investment" on Monday June 3rd from 2:30-4:00 pm ET, highlighting program areas in both Intrexon Health and Intrexon Bioengineering.
- Helen Sabzevari, PhD, President of Precigen, Inc., a wholly-owned subsidiary of Intrexon and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, will participate in the panel "Immuno-Oncology: Taking Immunotherapies to the Next Level" on June 6th from 10:30 am-12:00 pm ET.
The BIO International Convention in Philadelphia celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Attendees will take advantage of unparalleled business partnering, gain insights in hundreds of education sessions, and network with 16,000+ of biotech's most influential. Learn more at convention.bio.org.
The companies' presentations will not be webcast.
About Intrexon Corporation
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet through two operating units – Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information regarding Intrexon Corporation, contact:
Investor Contact: Steven Harasym Vice President, Investor Relations Tel: +1 (301) 556-9850 investors@dna.com | Corporate Contact: Marie Rossi, PhD Vice President, Communications Tel: +1 (301) 556-9850 publicrelations@dna.com |
View original content to download multimedia:http://www.prnewswire.com/news-releases/intrexon-to-participate-in-2019-bio-international-convention-300857242.html
SOURCE Intrexon Corporation
